SG Americas Securities LLC Has $13.99 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

SG Americas Securities LLC raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1,170.2% in the 4th quarter, HoldingsChannel reports. The fund owned 213,587 shares of the company’s stock after acquiring an additional 196,772 shares during the period. SG Americas Securities LLC’s holdings in AstraZeneca were worth $13,994,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. increased its position in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca during the third quarter worth $28,000. Albion Financial Group UT increased its position in shares of AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after buying an additional 248 shares during the period. Groupama Asset Managment increased its position in shares of AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after buying an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of AstraZeneca during the third quarter worth $45,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AZN has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Up 0.6 %

AstraZeneca stock opened at $68.60 on Friday. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The firm has a market capitalization of $212.73 billion, a price-to-earnings ratio of 32.82, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46. The firm’s fifty day moving average price is $66.26 and its two-hundred day moving average price is $74.28. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period last year, the firm earned $0.87 earnings per share. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, equities research analysts predict that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.